TITLE: Cohort profile: the Swiss Cerebral Palsy Registry (Swiss-CP-

2 Reg) cohort study

4 Authors:

1

3

8

25

- 5 Fabiën N. Belle^{1, 2}, Sandra M. Hunziker¹, Joël Fluss³, Sebastian Grunt⁴, Stephanie Juenemann⁵,
- 6 Christoph Kuenzle⁶, Andreas Meyer-Heim⁷, Christopher J. Newman^{8, 9}, Gian Paolo Ramelli¹⁰,
- 7 Peter Weber⁵, Claudia E. Kuehni^{1,4,11}, Anne Tscherter^{1,4}
- ¹Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
- ²Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne,
- 11 Switzerland.
- ³Paediatric Neurology Unit, University Children's Hospital Geneva, Geneva, Switzerland
- ⁴Division of Neuropediatrics, Development and Rehabilitation, Department of Pediatrics,
- 14 Inselspital Bern, University Hospital, University of Bern, Switzerland
- ⁵Division of Neuropaediatric and Developmental Medicine, University Children's Hospital of
- 16 Basel (UKBB), University of Basel, Basel, Switzerland.
- ⁶Children's Hospital of Eastern Switzerland, St Gallen, Switzerland.
- ⁷Swiss Children's Rehab, University Children's Hospital Zurich, Affoltern am Albis, Switzerland.
- 19 Paediatric Neurology and Neurorehabilitation Unit, Lausanne University Hospital (CHUV),
- 20 Lausanne, Switzerland.
- ⁹University of Lausanne (UNIL), Lausanne, Switzerland
- ¹⁰Gian Paolo Ramelli, Neuropaediatric Unit, Paediatric Institute of Southern Switzerland,
- 23 Ospedale San Giovanni, Bellinzona, Switzerland.
- ¹¹Children's University Hospital, Inselspital, University of Bern, Bern, Switzerland

Correspondence: Anne Tscherter, PD Dr. phil. Nat., Dr. sci. med., Institute of Social and 27 28 Preventive Medicine, University of Bern, Mittelstrasse 43, CH-3012 Bern, 29 anne.tscherter@ispm.unibe.ch 30 31 Authors' last names: Belle (ORCID: 0000-0002-0037-4817), Hunziker (ORCID: 0000-0003-32 3914-4987), Fluss (ORCID: 0000-0002-6413-162X), Grunt, Juenemann, Kuenzle, Meyer-33 Heim (ORCID: 0000-0002-6094-6717), Newman (ORCID: 0000-0002-9874-6681), Ramelli, Weber, Kuehni (ORCID: 0000-0001-8957-2002), Tscherter (ORCID: 0000-0002-6972-482X). 34 35 36 Keywords: Cerebral Palsy, Swiss Cerebral Palsy Registry, Patient registry, Paediatrics, 37 Epidemiology, Europe

SUMMARY BACKGROUND: Cerebral Palsy (CP) is a group of permanent disorders of movement and posture that follows injuries to the developing brain. It results in motor dysfunction and a wide variety of comorbidities like epilepsy, pain, speech, hearing and vision disorders, cognitive dysfunction, and eating and digestive difficulties. Central data collection is essential to study the epidemiology, clinical presentations, care, and quality of life of patients affected by CP. CP specialists founded the Swiss Cerebral Palsy Registry (Swiss-CP-Reg) in 2017. This paper describes the design, structure, aims and achievements of the Swiss-CP-Reg and presents first results. **METHODS:** Swiss-CP-Reg records patients of any age suffering from CP who are born. treated, or live in Switzerland. It collects data from medical records and reports, from questionnaires answered by patients and their families, and from data linkage with routine statistics and other registries. The registry contains information on diagnosis, clinical presentation, comorbidities, therapies, personal information, family history, and quality of life. RESULTS: From August 2017 to August 2021, 546 participants (55% males, mean age at registration 8 years (interguartile range IIQR]: 5-12) were enrolled in Swiss-CP-Reg. Most had been born at term (56%), were less than 2 years old at diagnosis (73%, median 9 months, IQR: 18-25), and were diagnosed with spastic CP (76%). Most (59%) live with a mild motor impairment (Gross Motor Function Classification System [GMFCS] level I or II), 12% with a moderate motor impairment (GMFCS level III), and 29% with a severe motor impairment (GMFCS level IV or V). In a subset of 170 participants, we measured intelligence quotient (IQ) and saw a reduced IQ by GMFCS scale increase. The Swiss-CP-Reg has a strong interest in research with currently 5 nested projects running, and many more planned. **CONCLUSIONS:** Swiss-CP-Reg collects and exchanges national data on people living with CP to answer clinically relevant questions. Its structure enables retrospective and prospective data collection and knowledge exchange between experts to optimise and standardise treatment and improve the health and quality of life of those diagnosed with CP in Switzerland.

ClinicalTrials.gov identifier: NCT04992871

39

40 41

42

43

44

45

46 47

48

49 50

51

52

5354

55 56

57

58

59

60

61

62 63

64

65

66

67

68

69 70

INTRODUCTION

72

73

74

75

76

77

78

79

80

81

82 83

84 85

86 87

88

89 90

91

92

93

94

95

96

97

98

99

100

101

102103

104

Cerebral palsy (CP) is a group of permanent disorders of movement, posture, and motor function causing activity limitation. With a prevalence of 1.5 to 2.5 per 1'000 live-born children [1], it is the most common cause of physical disability in children. It is estimated that approximately 3000 children and adolescents and 12'000 adults live in Switzerland with CP based on international data and extrapolated data from the eastern part of the country (St. Gallen) [2]. CP results from a non-progressive lesion or brain malformation that occurs during the prenatal, perinatal, or postnatal period, e.g., ischemic lesions of the neonatal brain or genetic predispositions leading to brain malformation [3]. CP shows a large variability in type and distribution of movement abnormality and degree of functional impairment. Besides motor dysfunction, persons with CP suffer from many comorbidities, including epilepsy, speech, hearing or vision disorders, cognitive dysfunction, eating and digestive difficulties, behavioural disorders, and secondary musculoskeletal problems including associated pain [1,3-5]. These comorbidities can restrict persons with CP in various dimensions of social life, such as education, play and sport activities, and work participation [6-10]. Within Switzerland, only 20% of adults with CP have paid employment in the primary labour market job [11]. Besides these restrictions persons with CP experience also their family's everyday life is influenced by their disability. The CP of a child can impact the (mental) health and well-being of affected parents [12-18] and limits siblings in their activities [19,20]. Currently, there is no cure for CP and patients often need lifelong support by an interdisciplinary team of specialists.

The involvement of an interdisciplinary team including many different specialists makes it difficult for researchers to obtain the full spectrum of patient data. A centralised data collection, where all information on people with CP can be linked, is therefore essential to optimize and standardise care, improve clinical surveillance, develop preventive strategies for comorbidities, and study the quality of life of affected people. Other countries have built up regional [21-23], or national [24-31] registries, or participate in networks [32,33]. In Switzerland, knowledge about CP in general and knowledge of supportive treatment in particular, is sparse. Previous research on CP in Switzerland included regional projects that focused on specific questions, such as epidemiologic research, work on neuroimaging and health related quality of live in unilateral spastic CP after neonatal arterial ischemic stroke [34-36], interventions to improve upper limb function in unilateral spastic CP [37-39], the early diagnosis of cerebral palsy in infants at risk [40], robot-assisted rehabilitation [41-43], hip reconstruction [44], gait analysis in children and young adult with CP [45,46], application patterns of physiotherapy (continuous vs. blocks) [47],

and behavioural and emotional problems [48]. Data has also been contributed to international studies [40,41,49,50]. In 2017 CP specialists from the entire country decided on a national collaboration and founded the Swiss Cerebral Palsy Registry (Swiss-CP-Reg) to collect national data and promote CP research in Switzerland. Swiss-CP-Reg aims to optimise treatment and improve the health and quality of life of children living with CP by establishing a platform for research and knowledge exchange between patients, healthcare providers, researchers, and other stakeholders. This paper describes the design, structure, aims, and achievements of the Swiss-CP-Reg and presents baseline characteristics of participants.

MATERIALS AND METHODS

Study design

105

106

107

108109

110111

112

113114

115

122

134

135

- Swiss-CP-Reg is a national patient registry (ClinicalTrials.gov registration number:
- 117 NCT04992871) that collects medical and socio-demographic data on people with CP. Persons
- living with CP who give their consent are registered in Swiss-CP-Reg, and their data is currently
- 119 collected at regular intervals at the paediatric clinics in Basel, Bellinzona, Bern, Geneva,
- Lausanne, St. Gallen, and Zurich. In the coming years, it will extend data collection to include
- smaller hospitals and medical practices and invite adults to participate.
- 123 Aims of the Swiss-CP-Reg
- The aims of the registry are, to
- 1. Identify all children, adolescents and adults living with CP across the country, characterize
- their phenotypes and determine incidence, prevalence, time trends and regional differences.
- 2. Document diagnostic evaluations, treatments, quality of life, morbidity, mortality, and risk
- 128 factors.
- 3. Establish a research platform for clinical, epidemiological, and basic research to support
- participant recruitment for population based as well as interventional studies and to answer
- questions on topics like health, health care, education, social aspects, and quality of life.
- 4. Establish a platform for knowledge exchange between clinics, researchers, therapists,
- national and cantonal health authorities, and international parties.

Study population and recruitment procedure

138

139140

141

142143

144

145

146

147

148149

150

151

152

153

154155

156

157

158

159

160

161

162163

164

165

166

167

Swiss-CP-Reg registers all children, adolescents, and adults diagnosed with CP who have been born, are treated, or live in Switzerland. The diagnosis is made based on the Surveillance of Cerebral Palsy in Europe (SCPE) decision tree [32]. To assure that only children who meet the inclusion criteria are included, registration of participants is restricted to paediatricians specialised in neurology, rehabilitation, or development and a confirmation of the diagnosis is required at the age of 5 years in case children are enrolled at an earlier age. We exclude participants with pure muscular hypotonia, neurometabolic diseases (e.g., neuronal storage diseases, leukodystrophies) and other progressive neurological diseases (e.g., spinocerebellar ataxias, hereditary spastic paraplegia, Rett syndrome, epileptic encephalopathy). Physicians in clinics or practices identify eligible participants according to their clinical diagnosis and recruit them during routine medical consultations (Figure 1). Physicians inform eligible participants and caregivers and collect informed consent during their consultations. Study information and consent forms are available in four languages, French, German, Italian, and English. Those who provide informed consent are registered in the Swiss-CP-Reg. For those who do not consent, the registry collects an anonymized minimal data set consisting of year of birth, year of death (if applicable), sex, gestational age, birth weight, and CP type (Table 1). Data collection and data sources The Swiss-CP-Reg collects data through three main paths: 1) medical records from clinics and private practices; 2) questionnaires sent to patients and families; and 3) re-use of data from routine statistics and other registries. Medical data: Baseline medical data is collected in the participating clinics with the support of the registry team at the ISPM in Bern (Figure 1, Figure 2). The variable list is based on the SCPE dataset [51] and includes additional information on specific topics such as therapies, scoliosis, hip surveillance and pain (Table 1). Personal information collected from the medical records includes patient's name, contact information, date of birth, and contact information of the treating paediatrician. This is necessary to assure long term follow-up of the patients over decades and to invite patients and families to surveys and clinical studies. The dataset enables a detailed description of people living with CP, their clinical condition, diagnosis, measures of severity, and care. CP is diagnosed according to the SCPE guidelines, and severity and comorbidities are assessed using standardized tools such as Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), or Communication Function Classification System (CFCS). The use of these instruments allows to

record the change of the condition over time and to compare centres. Medical data are collected at regular intervals (Figure 2, Table 1). The main time-periods when data are collected are: at diagnosis (independent of age), at the age of 5, 10, and 15 years, and at the time of transition to adult care. Follow-up during adulthood is foreseen. When a patient is included in the Swiss-CP-Reg, available data up to the time point of enrolment is collected retrospectively. From then onwards, follow-up data is collected prospectively until death or loss to follow-up. Because of limited resources, centres now collect all available medical data from birth onwards for young children born after 2009. For adolescents born before 2010, we currently collect CP classification and severity data (GMFCS and intelligence quotient [IQ]). A retrospective data collection from birth until enrolment will follow for adolescents as soon as resources allow. Questionnaire data: Questionnaires are sent to people with CP in the registry and their families at regular intervals. Participation is voluntary and can be accepted or declined for each survey. Questionnaires cover different topics including healthcare, nutrition, sleep, pain, use of medical equipment, use of ancillary services, academic information including early childhood education level, school and professional integration, family history, health behaviour, quality of life, daily life participation, and needs and concerns of patients and families. Re-use of data from routine statistics and other registries: data from routine statistics and other registries can be linked to the Swiss-CP-Reg to answer specific research questions. For example, the Federal Statistics Office (FSO) Live Birth Registry can provide information on gestational age, birth weight, birth length, and parental age; the FSO Cause of Death and Stillbirth Statistics can contribute causes of death; Hospital Episode Statistics can inform on length of hospital stay; the Swiss Neonatal Network and Follow-up Group (SwissNeoNet) has information on the perinatal period for neonatal care data; and the Swiss Neuropediatric Stroke Registry includes infarct data. Authorisation for data linkage is needed from the data providers, e.g., from FSO or SwissNeoNet, for each analysis.

Database management and data flows

168

169

170

171172

173

174

175

176

177

178

179

180 181

182

183

184

185

186

187

188

189 190

191

192

193

194

195

196

197

198

The Swiss-CP-Reg database is built and managed using Research Electronic Data Capture (REDCap; Nashville, TN, USA) hosted at ISPM [52,53]. REDCap is a secure, web-based software platform supporting data capture for research studies. Captured personal data are strictly confidential. Access to the ISPM server and the Swiss-CP-Reg database is only given to

200

201

202

203204

205

206

207208

209

210

211

212

213

214

215

216

217

218219

220221

222

223224

225

226

227

228229

230

authorised personnel and data are handled with uttermost discretion. Daily, weekly, and monthly back-ups of the database are performed and securely stored on the ISPM servers. Most data are entered in the REDCap database directly by the local healthcare professionals or by members of the Swiss-CP-Reg team (Figure 2). The Swiss-CP-Reg team enters additional information that is sent to the ISPM via post or a secured e-mail address. Paper forms are securely locked at ISPM and can only be accessed by Swiss-CP-Reg team members. All paper forms, except for filled-out questionnaires, consent forms, and withdrawals, will be destroyed after digitalization and storage in the REDCap database. Data quality, analyses, and data sharing Patient's data is checked manually by the Swiss-CP-Reg team and by REDCap for completeness, plausibility, and consistency. Ambiguities are resolved in collaboration with treating healthcare professionals at the time of data entry or after the manual quality check. We randomly perform control checks to detect systematic mistakes during data entry. In addition, selected data points are cross-checked for plausibility with previously entered data. Data analyses are performed using dedicated programs (STATA, R). Pseudonymised data can be made available to other research projects when legal requirements are met. This includes data usage by regional, national, or international research projects. Researchers interested in collaborative work can contact the Swiss-CP-Reg team (swiss-cpreg@ispm.unibe.ch) to discuss planned projects or analyse existing data. The decision on collaboration is made by the Steering Board of the Swiss-CP-Reg. Governance, organisational structure, and funding Organisational structure In 2014 the setup of a national registry for CP in Switzerland was initiated by Dr. med. Christoph Kuenzle (Ostschweizer Kinderspital, St. Gallen). The setup was divided into three phases. In the preparation phase we defined the stakeholders, organizational structure, fundraising strategy, objectives, dataset, in- and exclusion criteria, participant recruitment, and data collection. During the following build-up phase, we applied for ethical approval, developed data transfer and use agreements and data collection guidelines, set up a REDCap database and dissemination tools, and requested funding. During the third phase, we started to recruit participants and collect data. We developed data quality checks and revised the initial dataset where needed.

We developed an inclusive and broad organizational structure, which comprises several specialised bodies. The steering board includes specialised paediatricians from all seven large Swiss child hospitals. The involvement of the steering board led to a harmonised national data collection and a more complete recording of a child's clinical picture. The operational management is located at ISPM Bern and supports the data providers in recruitment and data collection. It hosts and maintains the database, takes care of the legal aspects and public relations, and promotes research. The expert groups include specialists from different fields, who support the registry, such as geneticists, paediatric orthopaedic surgeons, physiotherapists. speech therapists, nutritionists, and parents of children or adolescents with CP. The general assembly includes representatives of clinical centres, national patient organisations, medical societies, and expert groups. They meet once per year to discuss ongoing research and promote study participation. The *clinical centres* provide support in data collection. Swiss-CP-Reg collaborates closely with the Swiss Research Platform for Paediatric Registries (SwissPedReg). This platform provides advice to registries in a build-up phase on for example the ethics application process, datasets and information collection, and organisational structure. Swiss-CP-Reg collaborates closely with national stakeholders, including patients and their families, patient organisations, clinics, medical societies, experts from various disciplines and regions, researchers, and international networks. All national stakeholders are included in the organisational structure of the registry. Swiss-CP-Reg also exchanges information with the collaborative network of CP registries across Europe (SCPE) and will apply for membership as soon as it reaches the prerequisites set by the SCPE e.g., the recruitment of patients also in small clinics and private practices. **Funding** The Swiss-CP-Reg (salaries, consumables, equipment) is financed by several funding bodies that include the 'Schweizerische Stiftung für das cerebral gelähmte Kind (Stiftung Cerebral)', Anna Mueller Grocholski Foundation, Swiss Academy of Childhood Disability (SACD), 'Hand in Hand Anstalt', 'Ostschweizer Kinderspital', the ACCENTUS Charitable Foundation (Walter Muggli Fund), and the Children's Research Centre (University Children's Hospital Zurich), Stiftung Cerebral was the main sponsor during the build-up phase of the registry.

Ethical approval

231

232

233

234235

236

237

238239

240

241

242

243

244

245

246

247

248249

250

251252

253

254

255256

257

258

259

In 2017, Swiss-CP-Reg obtained authorisation from the Cantonal Ethics Committee of Bern (2017-00873, risk category A, observational study) to collect national medical data from hospitals, clinics, and private practices, self-reported data from patients and families, to link data, and to retrospectively register deceased patients and patients lost to follow-up from clinics.

RESULTS

Status of patient registration and data collection

Active patient enrolment started in August 2017 in St. Gallen, followed in 2018 by Basel, Bellinzona, and Bern, in 2019 by Zurich and Geneva, and in 2020 by Lausanne. The Covid-19 pandemic slowed down recruitment in 2020 and 2021. By end of August 2021, Swiss-CP-Reg included data from 515 children and adolescents (0-17 years) and 31 adults (≥18 years), which represents an estimated 17% of all eligible children with CP in Switzerland. Among eligible participants who were identified and approached, only 30 (5%) refused participation and 4 (1%) were non-responders. For them we collected an anonymized minimal data set (**Table 2**). For about 80 patients the informed consent is pending; therefore, these patients have not yet been registered. By August 2021, we have collected baseline data at time of diagnosis for 400 participants, 5-year follow-up data for 266, 10-year follow-up data for 162, 15-year follow-up data for 31, and follow-up data at the timepoint of transition to adult care for two participants.

Characteristics of the study population

Table 2 summarises the basic socio-demographic and medical characteristics of the 546 registered participants. Slightly more than half were males (55%) with a median age at registration of 8 years (interquartile range [IQR]: 5-12 years). Most lived in the German speaking language region (82%); were born during the last ten years (year of birth 2011-2020, 52%), at term (gestational age ≥37 weeks, 56%), and were younger than 2 years at diagnosis (73%, median age 9 months, IQR: 18-25). The most prevalent type of diagnosis was spastic CP (76%) of whom 40% had bilateral and 36% had unilateral CP. Most (59%) live with a mild motor impairment (Gross Motor Function Classification System [GMFCS] level I, walks without limitations or II, walks with limitations). A moderate motor impairment was diagnosed in 12% (GMFCS level III, walks using a hand-held mobility device), and 29% had a severe motor

impairment (GMFCS level IV, self-mobility with limitations; may use powered mobility or V, transport in a manual wheelchair). In a subset of 170 children and adolescents we had collected information on the intelligence quotient (IQ). There was a clear decrease of IQ with increasing level of GMFCS (**Figure 3**).

Research projects

292

293

294

295

296 297

298

299

300

301

302

303

304 305

306 307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

The Swiss-CP-Reg collaborates with experts from various fields to realize research projects that aim to standardize and improve CP therapies. It supports the monitoring and research of a wide range of outcomes and data exchange via linkages with national and regional projects led by interested investigators. Ongoing projects address the following broad range of topics: medical cannabinoids, needs and wishes of patients and families, hip surveillance in a variety of Swiss paediatric clinics, risk factors and outcomes of unilateral CP and data linkage with SwissNeoNet (**Table 3**). In addition, master students conduct projects within the scope of Swiss-CP-Reg. Three master theses have been carried out addressing nutrition, the epidemiology of epilepsy, and magnetic resonance imaging classification, and two are currently addressing the relation between neuroimaging patterns and upper limb function in unilateral spastic CP and the timing, type and treatment of epileptic seizures and pain via a survey (SG, CK) Liliane Raess evaluated in her doctoral thesis (under supervision of AMH and Prof. Dr. Hubertus van Hedel) the perinatal history, imaging, outcome and treatment of the Zurich cohort of children with CP and compared this cohort to other registries. Second aim was to investigate the differences in early history and diagnostic process between the rare and common neurologic subtypes of CP in the Zurich cohort.

We pursue participation in international research projects, in particular with the SCPE. CK, member of the Swiss-CP-Reg steering board, is a part of the SCPE. He founded a CP registry in the canton of St. Gallen in 2013. He recruited most of the children and adolescents with CP born between 1995 and 2011 and collected their data [2]. The Swiss-CP-Reg participates in projects from the SCPE with the data from St. Gallen [54].

DISCUSSION

Swiss-CP-Reg led to standardised and harmonised collection of data on people with CP throughout Switzerland, facilitates data comparison between patients, regions, and countries,

324

325

326327

328

329

330

331

332

333

334

335

336

337338

339

340

341342

343

344

345

346347

348

349350

351

352

353

354

and has become a successful communication platform and a powerful tool for answering clinically relevant questions in CP. By August 2021, 546 patients have been enrolled. Comparison with other registries The aims of Swiss-CP-Reg are comparable to those of other CP registries [55], but in addition include the creation of a research platform and a network for knowledge exchange. Swiss-CP-Reg uses the SCPE definition of CP like most registries (64%) [55], which facilitates comparison. Many (46%) registries require a minimum age of survival (44%) or a minimum severity criterion (46%) for inclusion [55]. We do not restrict on these criteria to ensure the inclusion of severely affected patients, who deceased at young age, and of mild cases. This reduces selection bias. We collect a complete data set after consent. Other registries use permission by government body or opt-off options [56], which makes recruitment easier. Most CP registries are governmentally funded (72%), others are supported by non-profit organizations/charities (12%) as Swiss-CP-Reg [55]. Preliminary results show that CP classification, severity, and prevalence of comorbidities are in line with other European countries [5,57-59]. Most participants are males, are diagnosed with a spastic bilateral CP subtype, and have mild motor impairment (GMFCS levels I or II) in line of expectation [5,57,58]. Strengths and limitations The successful start of the Swiss-CP-Reg is in large parts indebted to its steering board. It has been a bottom-up approach with all large Swiss clinics being represented. We strived to reach consensus on a fully standardised and complete data collection. The board did also set up a thorough methodology for patient identification and registration, individualised for each clinic. The continuous motivation of local medical staff and optimization of recruitment and data collection by steering board members is important since recruitment and data collection is time consuming. All steering board members are dedicated and have a broad national and international network, which facilitates funding and connections with all stakeholders. This, together with the dissemination activity of the registry, creates a platform for interdisciplinary and interregional communication and knowledge exchange, one of the key goals of the registry. Another strength of the Swiss-CP-Reg is its role as research platform. Several other factors contribute to its success. First, we developed our data set based on the data set established by SCPE, which facilitates comparison with other registries. Secondly, Swiss-CP-Reg simplifies

research projects, as it obtained a broad ethical approval via a single informed consent to collect data from multiple sources, conduct surveys, and link data. We can also contact participants and their families directly to invite them for nested research. Finally, the registry can share partial coded data with research projects when they meet all legal requirements.

A limitation of the Swiss-CP-Reg is that it currently misses patients, who are diagnosed and treated in smaller clinics and private practices, and adult patients. This might have biased the distribution of severity, as it is possible that university hospitals treat more severe cases than smaller clinics and private practices. Efforts are made to become more inclusive by including all eligible patients. This will allow to make reliable statements about CP in Switzerland in the future and enable comparison with registries who apply different inclusion criteria, e.g., minimal severity of CP or exclusion of severely affected patients deceasing at young age. Secondly, the registry is limited now by retrospective data collection at time of recruitment. This will improve as soon as all patients already in follow-up have been included, so that recruitment can focus on incident cases, where data can be collected prospectively.

Future developments

In the coming years patient recruitment will be expanded to include more clinics and private practices. We will also expand recruitment to adult participants. We plan in-depth analyses of topics causing patients with CP and their families concern. Data will be collected via questionnaires. The studied topics will depend on the outcome of our current project on needs and wishes of patients with CP and their families. The aim of these surveys will be to support CP patients and their families by uncovering possible intervention strategies for each topic. An important focus of research is the participation of people with CP in daily activities. Children and adolescents with CP participate less in social life than their peers [9]. Participation can be increased by therapeutic measures, but data on the situation in Switzerland is lacking. Therefore, we are currently setting up a study to investigate carriers and facilitators for the participation of children with CP. This study will assess how children with CP and their families evaluate their participation in social life. In addition, future research projects of Swiss-CP-Reg aim to understand the aetiology of CP; uncover prognostic factors of CP during the perinatal phase; evaluate the occurrence of associated syndromes and anomalies; determine comorbidities; evaluate and improve treatments and therapies; detect regional differences of medical coverage, evaluate the impact of socio-economic factors on diagnosis, prognosis, and quality of life; develop strategies to enhance quality of life; uncover needs and concerns of

patients and families and evaluate early education and integration of CP patients in the school system and working environment. Further this data can be used for education of young medical staff members to train their diagnostic and therapeutic knowledge and skills to ensure improvement the care of patients suffering from cerebral palsy in future.

CONCLUSIONS

The Swiss-CP-Reg is now established in Switzerland, generates rich information on people living with CP and has facilitated the development of national and international research projects in various fields. Swiss-CP-Reg serves as an instrument for medical care, clinical and epidemiological research, the assessment of health care structures, and the evaluation of medical procedures to increase our understanding of cerebral palsy, explore causes of CP and associated conditions, and improve clinical practice.

ACKNOWLEDGMENTS

The authors express their gratitude to Dr. Christoph Kuenzle who initiated the Swiss-CP-Reg and all local hubs of Swiss Research Network of Clinical Paediatric Hubs (SwissPedNet) for their support for patient recruitment and data collection. We thank all patients in the Swiss-CP-Reg and their families for taking part. We thank all the physicians and local study teams who helped identify and register patients and worked closely with us throughout building the Swiss-CP-Reg. We are grateful to Prof. Dr. Thomas Dreher, Dr. Anne Girardet, Prof. Dr. Hubertus van Hedel, and Prof. Dr Christina Schulze for their collaboration on various projects and to the SACD for hosting the general assembly of Swiss-CP-Reg during their annual conference. We are thankful to our sponsors (see 'Funding'), without whom this work would not be possible. SwissPedReg, member of the SwissPedNet, supports the Swiss-CP-Reg with its research infrastructure.

CONFLICTS OF INTEREST

No conflict of interest.

417	ABBREVIATIONS	
418	CFCS	Communication Function Classification System
419	CP	Cerebral Palsy
420	FSO	Federal Statistics Office
421	GMFCS	Gross Motor Function Classification System
422	ISPM	Institute of Social and Preventive Medicine
423	IQ	Intelligence quotient
424	MACS	Manual Ability Classification System
425	REDCap	Research Electronic Data Capture
426	SACD	Swiss Academy of Childhood Disability
427	SCPE	Surveillance of Cerebral Palsy in Europe
428	Swiss-CP-Reg	Swiss Cerebral Palsy Registry
429	SwissNeoNet	Swiss Neonatal Network and Follow-up Group
430	SwissPedNet	Swiss Research Network of Clinical Paediatric Hubs
431	SwissPedReg	Swiss Research Platform for Paediatric Registries

REFERENCES


- 432 1. Graham, H.K.; Rosenbaum, P.; Paneth, N.; Dan, B.; Lin, J.P.; Damiano, D.L.; Becher, J.G.; 433 Gaebler-Spira, D.; Colver, A.; Reddihough, D.S., et al. Cerebral palsy. *Nature reviews. Disease* 434 primers **2016**, *2*, 15082.
- Kuenzle, C.; Stojicevic, V.; Forni, R.; van Son, C.; Maier, O. Epidemiology of cerebral palsy in eastern switzerland (st. Gallen). *Developmental Medicine & Child Neurology* **2015**, *57*, 49-49.
- Rosenbaum, P.; Paneth, N.; Leviton, A.; Goldstein, M.; Bax, M.; Damiano, D.; Dan, B.;
 Jacobsson, B. A report: The definition and classification of cerebral palsy april 2006.
 Developmental medicine and child neurology. Supplement 2007, 109, 8-14.
- Hollung, S.J.; Bakken, I.J.; Vik, T.; Lydersen, S.; Wiik, R.; Aaberg, K.M.; Andersen, G.L.
 Comorbidities in cerebral palsy: A patient registry study. *Developmental medicine and child neurology* 2020, *62*, 97-103.
- Jonsson, U.; Eek, M.N.; Sunnerhagen, K.S.; Himmelmann, K. Cerebral palsy prevalence, subtypes, and associated impairments: A population-based comparison study of adults and children. *Developmental medicine and child neurology* **2019**, *61*, 1162-1167.
- Fauconnier, J.; Dickinson, H.O.; Beckung, E.; Marcelli, M.; McManus, V.; Michelsen, S.I.; Parkes, J.; Parkinson, K.N.; Thyen, U.; Arnaud, C., *et al.* Participation in life situations of 8-12 year old children with cerebral palsy: Cross sectional european study. *BMJ (Clinical research ed.)* **2009**, 338, b1458.
- Michelsen, S.I.; Flachs, E.M.; Uldall, P.; Eriksen, E.L.; McManus, V.; Parkes, J.; Parkinson, K.N.;
 Thyen, U.; Arnaud, C.; Beckung, E., et al. Frequency of participation of 8-12-year-old children with cerebral palsy: A multi-centre cross-sectional european study. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society 2009, 13, 165-177.
- 455 8. Colver, A.; Thyen, U.; Arnaud, C.; Beckung, E.; Fauconnier, J.; Marcelli, M.; McManus, V.;
 456 Michelsen, S.I.; Parkes, J.; Parkinson, K., et al. Association between participation in life situations
 457 of children with cerebral palsy and their physical, social, and attitudinal environment: A cross458 sectional multicenter european study. *Archives of physical medicine and rehabilitation* **2012**, 93,
 459 2154-2164.
- Michelsen, S.I.; Flachs, E.M.; Damsgaard, M.T.; Parkes, J.; Parkinson, K.; Rapp, M.; Arnaud, C.;
 Nystrand, M.; Colver, A.; Fauconnier, J., et al. European study of frequency of participation of adolescents with and without cerebral palsy. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society 2014, 18, 282-294.
- Colver, A.; Rapp, M.; Eisemann, N.; Ehlinger, V.; Thyen, U.; Dickinson, H.O.; Parkes, J.;
 Parkinson, K.; Nystrand, M.; Fauconnier, J., et al. Self-reported quality of life of adolescents with cerebral palsy: A cross-sectional and longitudinal analysis. *Lancet (London, England)* 2015, 385, 705-716.
- Hundesamt für Sozialversicherungen BSV. Schweizerische eidgenossenschaft. Die medizinischen massnahmen in der invaliden- und krankenversicherung.
 https://www.parlament.ch/centers/documents/de/med-massnahmen-iv-kv-2013-03-15-d.pdf
 (14.07.2021),
- 472 12. Brehaut, J.C.; Kohen, D.E.; Raina, P.; Walter, S.D.; Russell, D.J.; Swinton, M.; O'Donnell, M.; 473 Rosenbaum, P. The health of primary caregivers of children with cerebral palsy: How does it compare with that of other canadian caregivers? *Pediatrics* **2004**, *114*, e182-191.
- 475 13. Raina, P.; O'Donnell, M.; Rosenbaum, P.; Brehaut, J.; Walter, S.D.; Russell, D.; Swinton, M.; 476 Zhu, B.; Wood, E. The health and well-being of caregivers of children with cerebral palsy. 477 *Pediatrics* **2005**, *115*, e626-636.
- 478 14. Yamaoka, Y.; Tamiya, N.; Moriyama, Y.; Sandoval Garrido, F.A.; Sumazaki, R.; Noguchi, H.
 479 Mental health of parents as caregivers of children with disabilities: Based on japanese nationwide
 480 survey. *PloS one* **2015**, *10*, e0145200.
- 481 15. Lach, L.M.; Kohen, D.E.; Garner, R.E.; Brehaut, J.C.; Miller, A.R.; Klassen, A.F.; Rosenbaum, P.L. The health and psychosocial functioning of caregivers of children with neurodevelopmental disorders. *Disabil Rehabil* **2009**, *31*, 741-752.

- 484 16. Sipal, R.F.; Schuengel, C.; Voorman, J.M.; Van Eck, M.; Becher, J.G. Course of behaviour problems of children with cerebral palsy: The role of parental stress and support. *Child Care Health Dev* **2010**, *36*, 74-84.
- 487 17. Majnemer, A.; Shevell, M.; Law, M.; Poulin, C.; Rosenbaum, P. Indicators of distress in families of children with cerebral palsy. *Disabil Rehabil* **2012**, *34*, 1202-1207.
- 489 18. Park, M.S.; Chung, C.Y.; Lee, K.M.; Sung, K.H.; Choi, I.H.; Kim, T.W. Parenting stress in parents of children with cerebral palsy and its association with physical function. *Journal of pediatric orthopedics. Part B* **2012**, *21*, 452-456.
- Tseng, M.H.; Chen, K.L.; Shieh, J.Y.; Lu, L.; Huang, C.Y.; Simeonsson, R.J. Child characteristics, caregiver characteristics, and environmental factors affecting the quality of life of caregivers of children with cerebral palsy. *Disabil Rehabil* **2016**, *38*, 2374-2382.
- Woodgate, R.L.; Edwards, M.; Ripat, J.D.; Rempel, G.; Johnson, S.F. Siblings of children with complex care needs: Their perspectives and experiences of participating in everyday life. *Child Care Health Dev* **2016**, *42*, 504-512.
- The cerebral palsy register of attica. https://eu-rd-platform.jrc.ec.europa.eu/scpe/scpe-network/members/greece_en (22.09.2021),
- The cerebral palsy register of central italy viterbo. https://eu-rd-platform.jrc.ec.europa.eu/scpe/scpe-network/members/italy_en (22.09.2021),
- The cerebral palsy register of innsbruck. https://eu-rd-platform.jrc.ec.europa.eu/node/10_sl (22.09.2021),
- Australian Cerebral Palsy Register, G. Australia and the australian cerebral palsy register for the birth cohort 1993 to 2006. *Dev Med Child Neurol* **2016**, *58 Suppl* 2, 3-4.
- 506 25. Shevell, M.I.; Dagenais, L.; Hall, N.; Consortium, R. Comorbidities in cerebral palsy and their relationship to neurologic subtype and gmfcs level. *Neurology* **2009**, *72*, 2090-2096.
- Alriksson-Schmidt, A.; Rimstedt, A.B.; Hagglund, G. Cpup- a multidisciplinary secondary prevention program for individuals with cerebral palsy. *Int J Integr Care* **2019**, *19*.
- 510 27. Uldall, P.; Michelsen, S.I.; Topp, M.; Madsen, M. The danish cerebral palsy registry. A registry on a specific impairment. *Dan Med Bull* **2001**, *48*, 161-163.
- 512 28. Yim, S.Y.; Yang, C.Y.; Park, J.H.; Kim, M.Y.; Shin, Y.B.; Kang, E.Y.; Lee, Z.I.; Kwon, B.S.; Chang, J.C.; Kim, S.W., *et al.* Korean database of cerebral palsy: A report on characteristics of cerebral palsy in south korea. *Ann Rehabil Med* **2017**, *41*, 638-649.
- 515 29. Badawi, N.; Honan, I.; Finch-Edmondson, M.; Hogan, A.; Fitzgerald, J.; Imms, C. The australian & new zealand cerebral palsy strategy. *Dev Med Child Neurol* **2020**, *6*2, 885.
- 517 30. Bufteac, E.G.; Andersen, G.L.; Torstein, V.; Jahnsen, R. Cerebral palsy in moldova: Subtypes, severity and associated impairments. *Bmc Pediatr* **2018**, *18*.
- 519 31. Almasri, N.A.; Saleh, M.; Abu-Dahab, S.; Malkawi, S.H.; Nordmark, E. Development of a cerebral palsy follow-up registry in jordan (cpup-jordan). *Child Care Health Dev* **2018**, *44*, 131-139.
- Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in europe: A collaboration of cerebral palsy surveys and registers. Surveillance of cerebral palsy in europe (scpe). Dev Med
 Child Neurol 2000, 42, 816-824.
- Hurvitz, E.A.; Gross, P.H.; Gannotti, M.E.; Bailes, A.F.; Horn, S.D. Registry-based research in cerebral palsy: The cerebral palsy research network. *Phys Med Rehabil Clin N Am* **2020**, *31*, 185-194.
- Wiedemann, A.; Pastore-Wapp, M.; Slavova, N.; Steiner, L.; Weisstanner, C.; Regényi, M.;
 Steinlin, M.; Grunt, S. Impact of stroke volume on motor outcome in neonatal arterial ischemic
 stroke. European journal of paediatric neurology: EJPN: official journal of the European
 Paediatric Neurology Society 2020, 25, 97-105.
- 531 35. Caspar-Teuscher, M.; Studer, M.; Regényi, M.; Steinlin, M.; Grunt, S. Health related quality of life 532 and manual ability 5 years after neonatal ischemic stroke. *European journal of paediatric* 533 *neurology : EJPN : official journal of the European Paediatric Neurology Society* **2019**, 23, 716-534 722.
- 535 36. Grunt, S.; Mazenauer, L.; Buerki, S.E.; Boltshauser, E.; Mori, A.C.; Datta, A.N.; Fluss, J.; Mercati, D.; Keller, E.; Maier, O., *et al.* Incidence and outcomes of symptomatic neonatal arterial ischemic stroke. *Pediatrics* **2015**, *135*, e1220-1228.

- Grunt, S.; Newman, C.J.; Saxer, S.; Steinlin, M.; Weisstanner, C.; Kaelin-Lang, A. The mirror illusion increases motor cortex excitability in children with and without hemiparesis.
 Neurorehabilitation and neural repair 2017, 31, 280-289.
- Bruchez, R.; Jequier Gygax, M.; Roches, S.; Fluss, J.; Jacquier, D.; Ballabeni, P.; Grunt, S.;
 Newman, C.J. Mirror therapy in children with hemiparesis: A randomized observer-blinded trial.
 Developmental medicine and child neurology 2016, 58, 970-978.
- Weisstanner, C.; Saxer, S.; Wiest, R.; Kaelin-Lang, A.; Newman, C.J.; Steinlin, M.; Grunt, S. The neuronal correlates of mirror illusion in children with spastic hemiparesis: A study with functional magnetic resonance imaging. *Swiss medical weekly* **2017**, *147*, w14415.
- 547 40. Datta, A.N.; Furrer, M.A.; Bernhardt, I.; Hüppi, P.S.; Borradori-Tolsa, C.; Bucher, H.U.; Latal, B.; 548 Grunt, S.; Natalucci, G. Fidgety movements in infants born very preterm: Predictive value for 549 cerebral palsy in a clinical multicentre setting. *Developmental medicine and child neurology* **2017**, 550 59, 618-624.
- van Hedel, H.J.A.; Severini, G.; Scarton, A.; O'Brien, A.; Reed, T.; Gaebler-Spira, D.; Egan, T.;
 Meyer-Heim, A.; Graser, J.; Chua, K., et al. Advanced robotic therapy integrated centers (artic):
 An international collaboration facilitating the application of rehabilitation technologies. Journal of neuroengineering and rehabilitation 2018, 15, 30.
- Meyer-Heim, A.; Ammann-Reiffer, C.; Schmartz, A.; Schäfer, J.; Sennhauser, F.H.; Heinen, F.;
 Knecht, B.; Dabrowski, E.; Borggraefe, I. Improvement of walking abilities after robotic-assisted locomotion training in children with cerebral palsy. *Archives of disease in childhood* 2009, *94*, 615-620.
- 559 43. Ammann-Reiffer, C.; Bastiaenen, C.H.; Meyer-Heim, A.D.; van Hedel, H.J. Effectiveness of robotassisted gait training in children with cerebral palsy: A bicenter, pragmatic, randomized, crossover trial (pelogait). *BMC pediatrics* **2017**, *17*, 64.
- Rutz, E.; Vavken, P.; Camathias, C.; Haase, C.; Jünemann, S.; Brunner, R. Long-term results and outcome predictors in one-stage hip reconstruction in children with cerebral palsy. *The Journal of bone and joint surgery. American volume* **2015**, *97*, 500-506.
- 565 45. Brégou Bourgeois, A.; Mariani, B.; Aminian, K.; Zambelli, P.Y.; Newman, C.J. Spatio-temporal gait analysis in children with cerebral palsy using, foot-worn inertial sensors. *Gait & posture* **2014**, 39, 436-442.
- Bonnefoy-Mazure, A.; De Coulon, G.; Armand, S. Self-perceived gait quality in young adults with cerebral palsy. *Developmental medicine and child neurology* **2020**, *6*2, 868-873.
- 570 47. Brunner, A.L.; Rutz, E.; Juenemann, S.; Brunner, R. Continuous vs. Blocks of physiotherapy for 571 motor development in children with cerebral palsy and similar syndromes: A prospective 572 randomized study. *Developmental neurorehabilitation* **2014**, *17*, 426-432.
- Weber, P.; Bolli, P.; Heimgartner, N.; Merlo, P.; Zehnder, T.; Kätterer, C. Behavioral and
 emotional problems in children and adults with cerebral palsy. European journal of paediatric
 neurology: EJPN: official journal of the European Paediatric Neurology Society 2016, 20, 270 274.
- 49. Araneda, R.; Sizonenko, S.V.; Newman, C.J.; Dinomais, M.; Le Gal, G.; Ebner-Karestinos, D.; Paradis, J.; Klöcker, A.; Saussez, G.; Demas, J., et al. Protocol of changes induced by early hand-arm bimanual intensive therapy including lower extremities (e-habit-ile) in pre-school children with bilateral cerebral palsy: A multisite randomized controlled trial. *BMC neurology* **2020**, *20*, 243.
- 582 50. Aurich-Schuler, T.; Warken, B.; Graser, J.V.; Ulrich, T.; Borggraefe, I.; Heinen, F.; Meyer-Heim,
 583 A.; van Hedel, H.J.; Schroeder, A.S. Practical recommendations for robot-assisted treadmill
 584 therapy (lokomat) in children with cerebral palsy: Indications, goal setting, and clinical
 585 implementation within the who-icf framework. *Neuropediatrics* **2015**, *46*, 248-260.
- 586 51. Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in europe (scpe): Scientific report 1998-2018; https://eu-rd-platform.jrc.ec.europa.eu/scpe_en, 2018.
- 588 52. Harris, P.A.; Taylor, R.; Minor, B.L.; Elliott, V.; Fernandez, M.; O'Neal, L.; McLeod, L.; Delacqua, 589 G.; Delacqua, F.; Kirby, J., *et al.* The redcap consortium: Building an international community of software platform partners. *Journal of biomedical informatics* **2019**, *95*, 103208.
- 591 53. Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (redcap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of biomedical informatics* **2009**, *42*, 377-381.


- 594 54. Sellier, E.; Goldsmith, S.; McIntyre, S.; Perra, O.; Rackauskaite, G.; Badawi, N.; Fares, A.; 595 Smithers-Sheedy, H.; Europe, S.C.P.; Register, A.C.P. Cerebral palsy in twins and higher 596 multiple births: A europe-australia population-based study. *Developmental Medicine and Child* 597 *Neurology* **2021**, *63*, 712-720.
- 598 55. Ashwal, S.; Russman, B.S.; Blasco, P.A.; Miller, G.; Sandler, A.; Shevell, M.; Stevenson, R.;
 599 Quality Standards Subcommittee of the American Academy of, N.; Practice Committee of the
 600 Child Neurology, S. Practice parameter: Diagnostic assessment of the child with cerebral palsy:
 601 Report of the quality standards subcommittee of the american academy of neurology and the
 602 practice committee of the child neurology society. *Neurology* **2004**, *62*, 851-863.
- Goldsmith, S.; McIntyre, S.; Smithers-Sheedy, H.; Blair, E.; Cans, C.; Watson, L.; Yeargin-Allsopp, M.; Australian Cerebral Palsy Register, G. An international survey of cerebral palsy registers and surveillance systems. *Dev Med Child Neurol* **2016**, *58 Suppl* 2, 11-17.
- 57. Surveillance of Cerebral Palsy in Europe (SCPE). Prevalence and characteristics of children with cerebral palsy in europe. *Developmental medicine and child neurology* **2002**, *44*, 633-640.
- Andersen, G.L.; Irgens, L.M.; Haagaas, I.; Skranes, J.S.; Meberg, A.E.; Vik, T. Cerebral palsy in norway: Prevalence, subtypes and severity. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society 2008, 12, 4-13.
- 611 59. Oskoui, M.; Coutinho, F.; Dykeman, J.; Jette, N.; Pringsheim, T. An update on the prevalence of cerebral palsy: A systematic review and meta-analysis. *Dev Med Child Neurol* **2013**, *55*, 509-519.
- 613 60. Robb, J.E.; Hägglund, G. Hip surveillance and management of the displaced hip in cerebral palsy. *Journal of children's orthopaedics* **2013**, *7*, 407-413.

Figure 1. Schematic chart of patient recruitment, data collection, and use of data of the Swiss Cerebral Palsy Registry



CP, cerebral palsy; dx, diagnosis; ISPM, institute of social and preventive medicine; transition, transition to adult care.


Figure 2. Scematic flow chart of Swiss-CP-Reg; data collection management and timelines



CP, cerebral palsy; Swiss-CP-Reg, Swiss Cerebral Palsy Registry

^{*} Medical follow-up data can be collected retrospectively if a participant is registered after diagnosis

Figure 3. Intelligence quotient distribution, by Gross Motor Function Classification System, in a subset of 170 child and adolescent included in the Swiss-CP-Reg



Gross Motor Function Classification System (GMFCS) is subdivided in level I, Walks without limitations; level II, Walks with limitations; level III, Walks using a hand-held mobility device; level IV, Self-Mobility with limitations; may use powered mobility, and level V, Transported in a manual wheelchair; intelligence quotient (IQ). The P-value calculated from Chi-Square statistics comparing GMFCS levels (2-sided) is <0.001.

Table 1. Description of the data collected in the Swiss Cerebral Palsy Registry and time points of assessment

		Dx	Follow-up ²
Patient information ¹			
Name, address, medic of death, parents' educ	Х	Х	
Medical data			
Date of examination/last consultation			Χ
Confirmation of CP diagnosis			X
Anthropometric data	Height, weight, head circumference	Χ	X
CP diagnosis	Age at diagnosis, post neonatal CP (cause, time of insult, ICD code)	Χ	
CP classification	CP type ³ , GMFCS, MACS	Χ	X
Syndromes and anomalies	Genetic analysis, diagnosed syndromes (ICD code), cardiac malformation (ICD code), additional congenital anomalies, hydrocephalus	X	X
Imaging	Type (US, MRI, CT), date, classification of results, side	Χ	X
Perinatal information	Maternal place of residence at birth, maternal infection during pregnancy, (trimester, pathogen), place of birth, gestational age (weeks and days) ³ , delivery mode, birth weight ³ , birth length, head circumference, multiple birth, Apgar score at 5 min, admission in neonatal care unit, convulsions, therapeutic hypothermia (active/passive)	X	
Cognition	Neurodevelopmental and cognitive assessments (date, type, result,)		X
Comorbidities			X
Musculoskeletal system	Pathological fractures, hip dislocation (date, side, MI), scoliosis (date, Cobb angle)		X
Treatments	Therapies (physio-, psychotherapy, occupational, equine- assisted, speech, and language therapy) surgeries, medical management, postural management		

AAC, Augmented and Alternative Communication; Apgar, Appearance, Pulse, Grimace, Activity, Respiration; CFCS, Communication Function Classification System; CP, Cerebral Palsy; CT, Computed Tomography; Dx, Diagnostic data: EDACS, Eating and Drinking Ability Classification System; Fu, Follow-up data; GMFCS, Gross Motor Function Classification System; ICD, International Classification of Disease; MACS, Manual Ability Classification System; MI; Migration Index; MRI, Magnetic Resonance Imaging; US, Ultra Sound; VSS, Viking Speech Scale.

¹Access to identifying information is stored with restricted access.

²Follow-up data at 5 (4-6) years, 10 (9-11) years, 15 (14-16) years, at transition to adult care, and follow-up data of adult CP patients (time-points of assessments to be defined). ³Part of minimal data set.

Table 2. Characteristics of study participants in the Swiss Cerebral Palsy Registry (N=546, status at 31.08.2021)

Characteristics	Registered		
Ondiacteristics	N^2	persons	
		n (%)	
Informed Consent	546		
Signed		512 (94)	
Refused		30 (5)	
Non-responder		4 (1)	
Sex	546		
Females		248 (45)	
Males		298 (55)	
Age at registration, years, median (IQR)	546	8 (5-12)	
<5		144 (26)	
5-10		191 (35)	
10-15		169 (31)	
>15		42 (8)	
Language region of Switzerland	546		
German speaking		448 (82)	
French speaking ¹		74 (14) [′]	
Italian speaking		24 (4)	
Year of birth	546	,	
1996-2000		9 (2)	
2001-2005		58 (11)	
2006-2010		195 (36)	
2011-2016		189 (35)	
2016-2020		95 (17) [°]	
Gestational Age, weeks	362		
<28		39 (11)	
28-31		60 (17)	
32-36		62 (17)	
≥37		201 (56)	
Age at diagnosis, months, median (IQR)	283	9 (18-25)	
<24	200	208 (73)	
25-48		57 (20)	
49- 72		10 (4)	
>72		8(3)	
CP Type ³	432	0(0)	
Spastic	.02	329 (76)	
Bilateral		172 (40)	
Unilateral		155 (36)	
Unknown		2 (<1)	
		` '	
Dyskinetic		49 (11) 55 (13)	
Ataxic	400	55 (13)	
GMFCS ³	402	450 (07)	
I Walks without limitations		150 (37)	
II Walks with limitations		87 (22)	
III Walks using a hand-held mobility device		49 (12)	

IV Self-mobility with limitations; may use powered mobility	64 (16)
V Transport in a manual wheelchair	52 (13)

CP, Cerebral palsy; GMFCS, Gross Motor Function Classification System; IQR, interquartile range.

Start of recruitment was delayed due to legal issues.

Data collection is ongoing.

Classifications at the last data collection

Table 3: Ongoing and finalised research projects and collaborations of Swiss Cerebral Palsy Registry (September 2021)

Principal investigator, place	Project	
PD Dr. med. S. Grunt, Bern	Prescription practices of medical cannabinoids in children with CP: Medical cannabinoids are prescribed to children with CP despite limited evidence. The aim of the study is to assess the prescription practices of cannabinoids in children with CP with a particular focus on indications and preparations used and how well cannabinoids are tolerated. Data are collected from physicians by an online survey.	
PD Dr. A. Tscherter, Bern	Needs and wishes of patients with CP and their families: Data on needs and wishes of children with CP and their families living in Switzerland is collected via questionnaires. The aim of this study is to uncover sources of concern by patients and families (such as quality of life, nutrition, communication, use of aids).	
Prof. Dr. med. T. Dreher, Zurich	Hip surveillance: Monitoring the hips of patients with CP is important to detect and treat luxation at an early stage. Several countries have implemented hip surveillance programs [60]. The aim of this project is to establish such a monitoring program in Switzerland. Currently, the data set and the data collection procedure are being validated in Zurich.	
Dr. M. Adams, PD Dr. A. Tscherter, Zurich, Bern	Swiss Neonatal Network & Follow-up Group (SwissNeoNet): Partial pseudonymized data from SwissNeoNet and Swiss-CP-Reg are regularly linked to identify missing children and facilitate collaborative research. In the first data linkage in August 2021, we could identify 186 preterm children not yet included in Swiss-CP-Reg.	
Dr. A. Girardet, PD Dr. J. Fluss, Geneva	Risk factors and outcomes of unilateral CP: Unilateral CP is the most common form of CP affecting up to 40% of patients [55]. This project assesses different motor and cognitive patterns in Swiss children with unilateral CP. The results are compared with imaging, clinical, and socio-demographic data.	